Kapil Dhingra, M.B.B.S. is chair of the LAVA Therapeutics board of directors. Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care and drug development. He served as vice president, head of the oncology disease biology leadership team and head of oncology clinical development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva® and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the boards of directors/supervisors of Black Diamond Therapeutics, Inc., Replimune, Inc., Inc., Autolus Therapeutics plc, Median Technologies, Servier, Curie Therapeutics and Kirilys Therapeutics. He previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, Exosome Diagnostics and Five Prime. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his bachelor of medicine-bachelor of surgery degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine in Atlanta.